Fecal microbiota potentiate checkpoint inhibitors, unleash microbiome startups

0
105
Fecal microbiota potentiate checkpoint inhibitors, unleash microbiome startups
Advertisement

Two papers published in Science provide the first clinical evidence that fecal microbial transplants (FMTs) can boost the anti-cancer efficacy of immune checkpoint inhibitors. At least eight microbiome companies have launched first-in-human trials pairing their microbiome agents with approved immunotherapies (Table 1) to satisfy the growing need to increase the proportion of patients responding to checkpoint inhibitors.

Access options

Subscribe to Journal

Get full journal access for 1 year

59,00 €

only 4,92 € per issue

Tax calculation will be finalised during checkout.

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.

Read More

Advertisement

LEAVE A REPLY

Please enter your comment!
Please enter your name here